AYTU BIOPHARMA, INC Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2014 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aytu Biopharma, Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2014 to Q2 2024.
  • Aytu Biopharma, Inc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $352K, a 60.9% decline year-over-year.
  • Aytu Biopharma, Inc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $2.91M, a 51.8% decline year-over-year.
  • Aytu Biopharma, Inc annual Share-based Payment Arrangement, Expense for 2024 was $2.91M, a 51.8% decline from 2023.
  • Aytu Biopharma, Inc annual Share-based Payment Arrangement, Expense for 2023 was $6.05M, a 15.2% increase from 2022.
  • Aytu Biopharma, Inc annual Share-based Payment Arrangement, Expense for 2022 was $5.25M, a 46.8% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $2.91M $352K -$548K -60.9% Apr 1, 2024 Jun 30, 2024 10-K 2024-09-26
Q1 2024 $3.46M $811K -$91K -10.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $3.55M $820K -$2.25M -73.3% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $5.8M $930K -$247K -21% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $6.05M $900K -$330K -26.8% Apr 1, 2023 Jun 30, 2023 10-K 2024-09-26
Q1 2023 $6.38M $902K -$368K -29% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $6.74M $3.07M +$1.84M +150% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $4.91M $1.18M -$342K -22.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $5.25M $1.23M +$141K +12.9% Apr 1, 2022 Jun 30, 2022 10-K 2023-10-12
Q1 2022 $5.11M $1.27M -$252K -16.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $5.36M $1.23M +$721K +142% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-21
Q3 2021 $4.64M $1.52M +$1.06M +234% Jul 1, 2021 Sep 30, 2021 10-Q/A 2023-02-21
Q2 2021 $3.57M $1.09M +$601K +123% Apr 1, 2021 Jun 30, 2021 10-K 2022-09-27
Q1 2021 $2.97M $1.52M +$1.26M +477% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $1.72M $508K +$346K +214% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $1.37M $455K +$290K +176% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $1.08M $488K +$189K +63.2% Apr 1, 2020 Jun 30, 2020 10-K 2021-09-28
Q1 2020 $890K $264K -$113K -30% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $1M $162K -$32K -16.5% Oct 1, 2019 Dec 31, 2019 10-Q 2020-02-14
Q3 2019 $1.04M $165K +$13K +8.55% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $1.02M $299K +$149K +99.3% Apr 1, 2019 Jun 30, 2019 10-K 2020-10-06
Q1 2019 $873K $377K +$310K +463% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $563K $194K +$81K +71.7% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 $482K $152K -$115K -43.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $597K $150K -$179K -54.4% Apr 1, 2018 Jun 30, 2018 10-K 2019-09-26
Q1 2018 $776K $67K -$1.25M -94.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 $2.03M $113K -$350K -75.6% Oct 1, 2017 Dec 31, 2017 10-Q/A 2019-05-14
Q3 2017 $2.38M $267K -$852K -76.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $3.23M $329K Apr 1, 2017 Jun 30, 2017 10-K 2018-09-06
Q1 2017 $1.32M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 $463K +$280K +153% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-08
Q3 2016 $1.12M +$1.05M +1546% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q4 2015 $791K $183K -$93K -33.7% Oct 1, 2015 Dec 31, 2015 10-Q 2016-02-11
Q3 2015 $884K $68K -$134K -66.3% Jul 1, 2015 Sep 30, 2015 10-Q 2015-11-06
Q2 2015 $1.02M $268K Apr 1, 2015 Jun 30, 2015 10-K 2015-09-30
Q1 2015 $272K +$188K +224% Jan 1, 2015 Mar 31, 2015 10-Q 2015-05-19
Q4 2014 $276K Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-11
Q3 2014 $202K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q1 2014 $84K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.